Valuation: Indivior Pharmaceuticals, Inc.

Capitalization 482.81Cr 410.2Cr 375.59Cr 354.67Cr 658.5Cr 46TCr 666.13Cr 4.45TCr 1.73TCr 22TCr 1.81TCr 1.77TCr 76TCr P/E ratio 2026 *
12.5x
P/E ratio 2027 * 11.5x
Enterprise value 488.26Cr 414.83Cr 379.83Cr 358.68Cr 665.93Cr 46TCr 673.65Cr 4.5TCr 1.75TCr 22TCr 1.83TCr 1.79TCr 76TCr EV / Sales 2026 *
3.88x
EV / Sales 2027 * 3.44x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5d. change 1-year change 3-years change Capi.($)
+1.56%+5.27%+49.52%-20.18% 482.81Cr
-1.22%+4.32%+25.52%+127.90% 87TCr
-0.94%-3.19%+41.46%+36.78% 54TCr
-1.13%-4.07%+7.77%+36.94% 36TCr
-0.30%-0.60%+18.90%+11.56% 33TCr
-0.45%-2.04%+30.61%+11.10% 28TCr
-0.13%-0.70%+24.07%+20.63% 28TCr
-1.11%+2.86%+41.94%-4.57% 28TCr
-2.02%+4.19%-32.47%-49.45% 21TCr
-0.61%-4.96%+19.30%+39.13% 18TCr
Average -0.61%-0.36%+22.66%+20.98% 36.78TCr
Weighted average by Cap. -0.53%+0.24%+23.30%+45.89%

Financials

2026 *2027 *
Net sales 125.79Cr 106.87Cr 98Cr 92Cr 171.56Cr 12TCr 173.55Cr 1.16TCr 451.93Cr 5.69TCr 471.84Cr 462.05Cr 20TCr 128.74Cr 109.37Cr 100.15Cr 95Cr 175.58Cr 12TCr 177.62Cr 1.19TCr 462.51Cr 5.83TCr 482.89Cr 472.88Cr 20TCr
Net income 41Cr 35Cr 32Cr 30Cr 57Cr 3.91TCr 57Cr 382.17Cr 148.91Cr 1.88TCr 155.47Cr 152.24Cr 6.48TCr 45Cr 39Cr 35Cr 33Cr 62Cr 4.29TCr 63Cr 419.46Cr 163.43Cr 2.06TCr 170.63Cr 167.09Cr 7.12TCr
Net Debt 5.45Cr 4.63Cr 4.24Cr 4Cr 7.43Cr 513.67Cr 7.52Cr 50Cr 20Cr 246.6Cr 20Cr 20Cr 852.64Cr -40Cr -34Cr -31Cr -30Cr -55Cr -3.8TCr -56Cr -371.97Cr -144.93Cr -1.83TCr -151.32Cr -148.18Cr -6.31TCr
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
39.60USD
Average target price
51.50USD
Spread / Average Target
+30.05%

Quarterly revenue - Rate of surprise